First four-week supply price: KRW 129,800
About half the price of Mounjaro
Somewhat less effective at reducing weight
Price competitiveness and weight-loss efficacy are key to success

Hanmi Pharmaceutical’s “Efe” (generic name: efpeglenatide), the first domestically developed obesity treatment in the glucagon-like peptide-1 (GLP-1) class, will be available by prescription at some medical institutions starting October 29. The supply price for the first four weeks is about 130,000 won, roughly half the price of Mounjaro. Industry and market watchers are focused on whether Efe, which is positioned on the basis of its relatively low price and clinical results in Korean patients, can establish itself in Korea’s obesity drug market.

Product image of Hanmi Pharmaceutical's "Efe," an obesity treatment in the glucagon-like peptide-1 (GLP-1) class. Hanmi Pharmaceutical

Product image of Hanmi Pharmaceutical's "Efe," an obesity treatment in the glucagon-like peptide-1 (GLP-1) class. Hanmi Pharmaceutical

View original image

According to industry sources on October 29, the supply price for Efe’s lowest dose for the first four weeks has been set at 129,800 won. This gives it a price advantage over competing products Mounjaro (270,000 won) and Wegovy (210,000 won). Efe’s supply prices by dose are approximately 24,200 won for 2 mg, 40,700 won for 4 mg, 57,200 won for 6 mg, 69,300 won for 8 mg, and 74,800 won for 10 mg. By treatment period, the price is 228,800 won for weeks 5–8 and 277,200 won for weeks 9–12. From week 13 onward, a four-week course costs 299,200 won. Patients’ actual out-of-pocket costs are expected to be somewhat higher than the supply prices.


South Korea’s obesity drug market is currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, which launched in August last year, forming a two-horse race. Efe is a new challenger entering the market. Hanmi Pharmaceutical plans to gain market share in South Korea’s GLP-1 obesity drug market, which has grown to 2 trillion won annually, and create a three-way contest.


While Efe has a price advantage, its weight-loss effect is reportedly somewhat less pronounced than that of Mounjaro or Wegovy. Efe acts on GLP-1 receptors distributed in the central nervous system and gastrointestinal tract. It suppresses appetite and slows the rate at which food leaves the stomach, helping users feel full for longer. It comes in five doses: 2 mg, 4 mg, 6 mg, 8 mg, and 10 mg. Treatment starts at 2 mg, with the dose increased in stages until the patient reaches 10 mg.


According to Hanmi Pharmaceutical, a Phase 3 clinical trial involving 448 Korean patients with obesity found that the group treated for 40 weeks had an average weight loss of 9.75%. Some patients lost up to 30% of their body weight. In the global Phase 3 STEP-1 trial, Wegovy recorded an average weight loss of 14.9% over 68 weeks. In the global Phase 3 SURMOUNT-1 trial, Mounjaro recorded an average weight loss of 20.9% over 72 weeks at its highest dose of 15 mg. However, direct comparisons are limited because the trial durations and patient populations differed.



The market is watching to see how much Efe’s identity as a “K-obesity drug” will influence consumer choices. Hanmi Pharmaceutical is emphasizing that domestic companies handled the entire process, from identifying the candidate compound to commercialization, and that it has clinical trial results specifically from Korean patients. A Hanmi Pharmaceutical representative said, “We will work to improve patients’ access to treatment through thorough quality management and a reasonable pricing structure so that we can establish ourselves successfully in the domestic market,” adding, “We will do our best to help improve the quality of life of patients with obesity.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing